Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-TROP2-01
- Development stage
- Unknown
- Lead developer
- Fudan University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
68Ga-TROP2-01 is a radiopharmaceutical diagnostic tracer developed by Fudan University for positron emission tomography (PET) imaging. It consists of a TROP2-targeting nanobody (specifically Nb107) labeled with the positron-emitting radioisotope Gallium-68 (68Ga). TROP2 (Trophoblast cell-surface antigen 2) is a transmembrane glycoprotein overexpressed in various epithelial tumors, including breast cancer. The tracer is used to non-invasively assess TROP2 expression levels in vivo, which can help predict the efficacy of TROP2-targeted therapies, such as antibody-drug conjugates (ADCs) like sacituzumab govitecan or datopotamab deruxtecan. In clinical trials at Fudan University, it is being evaluated alongside 18F-FDG PET/CT to select patients and monitor responses in advanced HER2-negative breast cancer.
- Other names
- 68Ga-TROP2 PETGallium-68 TROP2-targeting tracerGallium68 TROP2-targeting tracerGallium 68 TROP2-targeting tracer68Ga-TROP2-Fudan University-breast cancer
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on 68Ga-TROP2-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-TROP2-01.